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background: Many patients with atrial fibrillation (AF) have comorbid cardiovascular diseases requiring concomitant use of dual (DOAT) or triple 
(TOAT) oral antithrombotic therapy, but their outcomes have not been well defined. We assessed outcomes associated with use of dual or triple 
therapy in AF patients undergoing electrical cardioversion (ECV).
methods: We studied 3,191 consecutive patients who underwent ECV from 2000 to 2013 and were discharged on antithrombotic agents. Patients 
were divided into 3 groups according to their antithrombotic regimen at discharge: warfarin only (oral antithrombotic therapy; OAT), warfarin+aspirin 
or clopidogrel (DOAT), and warfarin+aspirin+clopidogrel (TOAT). Survival, major adverse cardiovascular events, and bleeding requiring hospitalization 
or blood transfusion were examined.
results: In this cohort, 53.0%, 44.0%, and 3.0% of patients were discharged on OAT, DOAT and TOAT respectively. Compared with patients on OAT, 
those on DOAT and TOAT were more likely to be male (64.1% vs 68.1% vs 82.1%, p<0.02 for both) and older (mean age 66.8±12.7 vs 70.4±11.2 
vs 72.3±10.4 years, p<0.0001 for both), and to have higher CHADS2 scores (mean 1.5±1.2 vs 2.0±1.3 vs 2.3±1.3, p<0.001 for both) and prior 
percutaneous coronary interventions (4.3% vs 17.2% vs 71.0%, p<0.0001 for both). There was no significant between-group difference in survival at 
30 days (p=0.57) or 1 year (p=0.59). In a subgroup analysis of Olmsted County residents (n=615), 50.3%, 46.3% and 3.4% were discharged on OAT, 
DOAT and TOAT respectively. Similarly, compared with patients on OAT (mean CHADS2 1.8±1.2), those on DOAT (2.2±1.3) and TOAT (2.7±1.2) had 
higher CHADS2 scores (p<0.005 for both). There was no significant difference in major bleeding (8.6% vs 11.3% vs 5.6%, p=0.69) or cerebrovascular 
events (2.5% vs 2.9% vs 0%, p=0.76) among the 3 groups at 1-year follow-up.
conclusion: In patients who underwent ECV for AF, use of DOAT or TOAT was not associated with increased clinically significant bleeding or 
decreased short-term survival. These findings suggest that the short-term concomitant use of dual antiplatelet therapy with warfarin is generally safe 
in patients who have recently undergone ECV.
